Notes
CHMP = Committee for Medicinal Products for Human Use
Reference
European Medicines Agency. EMA review of Picato concludes medicine's risks outweigh its benefits. Internet Document : [2 pages], 17 Apr 2020. Available from: URL: https://www.ema.europa.eu/en/news/ema-review-picato-concludes-medicines-risks-outweigh-its-benefits
Rights and permissions
About this article
Cite this article
EMA: risks of ingenol mebutate use outweigh its benefits. Reactions Weekly 1802, 2 (2020). https://doi.org/10.1007/s40278-020-77920-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-77920-x